報價延遲最少15分鐘:2024/12/24 12:37 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1072 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-299.06/-0.39
|
|
企業價值
6.27M
|
| 資產負債 |
|
每股賬面淨值
0.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:37 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain. |